Our mission is to provide the medical community with multi-disciplinary educational tools that address their clinical needs and help in their daily clinical practice.

The introduction of biologic therapies to treat a wide variety of immune-mediated inflammatory diseases (IMIDs), in rheumatology, gastroenterology, dermatology and ophthalmology, among others, had a significant impact on the way these diseases are treated. However, the high cost of biologics has led to big differences in their adoption across the competent regulatory authorities of countries, partly due to the differences in reimbursement systems. Consequently, many patients eligible, from a clinical perspective, to receive a biologic treatment do not receive the adequate treatment due to cost constraints, which adds to their disease burdens and affects their quality of life.

Biosimilars are approved by the competent regulatory authorities based on robust evidence of biosimilarity obtained from comprehensive quality, physicochemical and biological comparisons, together with pharmacokinetic studies and confirmatory clinical efficacy studies. Biosimilars are high quality, affordable alternatives to originator biologics. The potential cost savings from the introduction of biosimilars are believed to help alleviate the ever-increasing pressure on healthcare systems and to benefit patients by shifting resources and allowing more patients eligible for a biologic to be treated in a timely, efficient and sustained manner.

This website has been developed and funded by Biogen and is intended for healthcare professionals in Switzerland.